Lenacapavir 463.5mg/1.5mL (309mg/mL); soln for SC inj; preservative-free. Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between capsid ...

There is a new long-acting drug for people with highly resistant HIV who have, until now, had limited medication options. On December 22, the federal Food and Drug Administration approved Gilead ...

Sunlenca (300 mg tablet and 463.5 mg/1.5 mL injection) [ (lenacapavir)] is a first-in-class, long-acting HIV capsid inhibitor indicated for the treatment of HIV infection, in combination with other ...

SILVER SPRING, Md., Dec. 22, 2022 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Sunlenca (lenacapavir), a new type of antiretroviral medication for adult patients living with ...

The U.S. Food and Drug Administration has approved Sunlenca (lenacapavir), a new type of antiretroviral medication for adult patients living with HIV-1 whose HIV infection cannot be successfully ...

The Food and Drug Administration has approved Sunlenca, an injectable therapy to suppress HIV for patients who suffered drug resistance to other regimens. Experts say the new injectable, which works ...

(Reuters) -The U.S. Food and Drug Administration (FDA) on Thursday approved Gilead Sciences Inc's Sunlenca therapy for HIV infections, paving the way for a drug that requires less frequent dosing than ...

Twice-yearly shots used to treat AIDS were 100% effective in preventing new infections in women, according to study results published Wednesday. There were no infections in the young women and girls ...

Twice-yearly shots used to treat AIDS were 100% effective in preventing new infections in women, according to a new study. There were no infections among the young women and girls who received the ...

Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between capsid protein (p24) subunits in hexamers. Surface plasmon resonance sensorgrams ...

FILE PHOTO: The logo of Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California (Reuters) - The U.S. Food and Drug Administration (FDA) on Thursday approved Gilead Sciences Inc's ...